Natural Selection, Inc.

October 20, 2008
Gary B. Fogel and V. William Porto Publish Article on Composite Transcription Factor Binding Site Discovery in Nucleic Acids Research

San Diego, CA -- Dr. Gary B. Fogel, Chief Executive Officer and Vincent W. Porto, President of Natural Selection, Inc., in collaboration with researchers at Eli Lilly & Co. (Indianapolis, IN) have published a paper titled "Evolutionary computation for discovery of composite transcription factor binding sites" in the journal Nucleic Acids Research (NAR) (doi: 10.1093/nar/gkn738). This new research highlights the several improvements to an evolutionary algorithm for transcription factor binding site discovery that allows detection of transcription factor binding sites of different sizes and complexity, some having experimental relationships with NFAT/AP-1. The article also indicates the importance of parameter tuning for transcription factor binding site discovery algorithms, especially those that make use of evolutionary optimization. To obtain a copy of the publication, please visit the NAR website at:

http://nar.oxfordjournals.org/cgi/reprint/gkn738?ijkey=9qsZofGHgMTDUzc&keytype=ref

Natural Selection, Inc. was founded in 1993 to address complex problems in industry, medicine, and defense. The company possesses unique expertise in computational intelligence techniques, including evolutionary computation, neural networks, and fuzzy logic. The corporation's research efforts support the discovery of new pharmaceuticals, the automated detection and discovery of important patterns and processes in bioinformatics and medical informatics, computer-assisted diagnosis, and a variety of military and industrial projects.

For more information, please contact:

Dr. Gary B. Fogel
CEO
Natural Selection, Inc.
9330 Scranton Rd.
Suite 150
San Diego, CA, 92121
tel: (858) 455-6449
fax: (858) 455-1560
gfogel [at] natural-selection [dot] com

and please visit our web site at http://www.natural-selection.com/.